

Silva Pharmaceuticals Limited

Un-Audited Financial Statements (Half Yearly)

For the Period from 01 July, 2025 to 31 December, 2025


SILVA PHARMACEUTICALS LTD.

Statement of Financial Position

As at 31 December, 2025

Particulars	Notes	Amount in Taka	
		31-Dec-25	30-Jun-25
ASSETS			
Non Current Assets		1,396,899,467	1,422,482,307
Property, Plant & Equipment	3.00	1,066,376,474	1,092,403,671
Intangible Assets	4.00	2,300,458	2,421,535
Right-of-use asset (ROU)	5.00	3,765,782	4,377,163
Capital work-in-Progress	6.00	324,456,753	323,279,938
Current Assets		790,467,882	829,838,514
Inventories	7.00	406,443,919	443,011,615
Trade and Other Receivables	8.00	209,317,860	229,617,998
Advances, Deposits and Prepayments	9.00	63,111,304	54,404,706
Fixed Deposits Receipts (FDR)	10.00	74,210,691	64,030,846
Cash and Cash Equivalents	11.00	37,384,108	38,773,349
Total Assets		2,187,367,349	2,252,320,821
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,041,548,725	2,113,040,947
Share Capital	12.00	1,365,000,000	1,365,000,000
Retained Earnings	13.00	676,548,725	748,040,947
Non-Current Liabilities		82,831,057	83,580,827
Deferred Tax Liabilities	14.00	81,102,362	81,270,136
Lease liabilities	15.00	1,728,695	2,310,691
Current Liabilities		62,987,567	55,699,047
Lease liabilities	15.00	1,037,218	1,066,472
Trade and Other Payables	16.00	14,190,692	9,971,279
Dividend Payable for the year 2023-2024		-	-
Unclaimed Dividend Account	17.00	136,569	139,158
Short Term Loan	18.00	29,261,084	28,219,737
Provision for Expenses	19.00	18,362,004	16,302,401
Total Liabilities		145,818,624	139,279,874
Total Equity & Liabilities:		2,187,367,349	2,252,320,821
Net Assets Value (NAV) per share	29.00	14.96	15.48
Number of Shares used to compute NAV		136,500,000	136,500,000

The annexed notes from an integral part of these financial statements.


Chairman


Chief Executive Officer (CC)


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;
Dated: January 29, 2026


Silva Pharmaceuticals Ltd
Statements of Profit or Loss and Other Comprehensive Income
For the Half-Year ended 31 December, 2025

Particulars	Notes	Amount in Taka			
		Half-Yearly Results		Quarterly Results	
		01/07/2025 to 31/12/2025	01/07/2024 to 31/12/2024	01/10/2025 to 31/12/2025	01/10/2024 to 31/12/2024
Revenue from Net Sales	20.00	174,973,907	201,634,883	88,559,817	102,530,143
Cost of goods sold	21.00	(123,144,082)	(141,545,937)	(58,022,709)	(69,432,631)
Gross Profit		51,829,825	60,088,946	30,537,108	33,097,512
Operating expenses		(120,790,708)	(118,165,165)	(64,143,988)	(58,532,077)
Administrative Expenses	22.00	(18,892,712)	(21,172,361)	(9,460,326)	(10,712,351)
Selling & Distribution Expenses	23.00	(101,897,996)	(96,992,804)	(54,683,662)	(47,819,726)
Operating Income		(68,960,883)	(58,076,219)	(33,606,880)	(25,434,565)
Financial expenses	24.00	(2,627,256)	(1,936,337)	(1,912,605)	(1,208,458)
Interest and Other income	25.00	2,228,257	3,365,493	1,228,352	1,926,005
Profit before WPPF and Welfare Fu		(69,359,882)	(56,647,063)	(34,291,133)	(24,717,018)
Worker's Profit Participation and Welfare Fund (WPP&WF)	26.00	-	-	-	-
Profit before Income Tax		(69,359,882)	(56,647,063)	(34,291,133)	(24,717,018)
Income Tax Expenses:	27.00	(2,132,340)	(2,389,270)	(1,289,412)	(1,387,930)
Current Tax Expenses	27.01	(2,300,114)	(2,115,332)	(1,373,702)	(1,250,961)
Deferred Tax expenses	27.02	167,774	(273,938)	84,290	(136,969)
Net Profit after tax		(71,492,222)	(59,036,333)	(35,580,545)	(26,104,948)
Other Comprehensive Income		-	-	-	-
Total comprehensive income for the period		(71,492,222)	(59,036,333)	(35,580,545)	(26,104,948)
Earnings Per Share (EPS)	28.00	(0.52)	(0.43)	(0.26)	(0.19)
Number of Shares used to compute EPS		136,500,000	136,500,000	136,500,000	136,500,000

The annexed notes from an integral part of these financial statements.



Chairman



Chief Executive Officer (CC)



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: January 29, 2026


SILVA PHARMACEUTICALS LTD.
Statement of Changes in Equity
For the Half-Year ended 31 December, 2025

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2025	1,365,000,000	748,040,947	2,113,040,947
Net profit after tax during the period	-	(71,492,222)	(71,492,222)
Balance as at 31 December, 2025	1,365,000,000	676,548,725	2,041,548,725

For the Half-Year ended 31 December, 2024

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2024	1,365,000,000	890,949,495	2,255,949,495
Net profit after tax during the period	-	(59,036,333)	(59,036,333)
Dividend for the year 2023-2024	-	(9,957,150)	(9,957,150)
Balance as at 31 December, 2024	1,365,000,000	821,956,012	2,186,956,012


The annexed notes from an integral part of these financial statements.



 Chairman



 Chief Executive Officer (CC)



 Director



 Chief Financial Officer



 Company Secretary

Place: Dhaka;
 Dated: January 29, 2026

SILVA PHARMACEUTICALS LTD.


Statement of Cash Flows

For the Half-Year ended 31 December, 2025


Particulars	Notes	Amount in Taka	
		01/07/2025 to 31/12/2025	01/07/2024 to 31/12/2024
Cash flows from Operating Activities			
Cash received from Customers	30.00	195,456,119	213,361,362
Cash received from non-operating income	31.00	2,046,183	3,395,773
Cash Paid to Suppliers	32.00	(58,295,514)	(68,927,899)
Cash Paid to Employees	33.00	(100,498,107)	(109,836,365)
Cash Paid for Others	34.00	(25,639,898)	(19,847,461)
Cash payment for Financial Expenses		(2,441,646)	(1,693,826)
Income Tax Paid	35.00	(790,041)	(1,378,745)
Net cash inflow/(outflow) from operating activities (A)*	37.00	9,837,096	15,072,839
Cash flows from Investing Activities			
Acquisition of Property, Plant and Equipment	36.00	(111,575)	-
Cash Payments for Capital Work-in-progress		(1,176,815)	(3,366,904)
Cash received/Payments from/to FDR		(10,179,845)	67,225,905
Net cash used in investing activities (B)		(11,468,235)	63,859,001
Cash flows from Financing Activities			
Short Term Loan received/(Repaid)		1,041,347	(11,750,055)
Cash payment towards lease liabilities		(796,860)	(860,295)
Cash Dividend Paid		(2,589)	(140,830)
Net cash used in financing activities (C)		241,898	(12,751,180)
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)		(1,389,241)	66,180,660
Cash and Cash Equivalents at the beginning of the period		38,773,349	28,642,612
Cash and Cash Equivalents at the end of the period	11.00	37,384,108	94,823,272
Net Operating Cash Flow Per Share (NOCFPS)	37.00	0.07	0.11

*Refer to Note 39.00 for a reconciliation between net profit with cash flows from operating activities.


The annexed notes from an integral part of these financial statements.


Chairman


Chief Executive Officer (CC)


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;

Dated: January 29, 2026

Silva Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-Audited)
For the Half-year Ended 31 December, 2025

1.00 About the Company

1.01 Formation and Legal Status:

Silva Pharmaceuticals Limited (the 'Company') was incorporated in Bangladesh on 24 April 2001 as a Private Limited Company and subsequently converted into Public Limited Company on 22 April, 2014 under the Companies Act, 1994 vide Registration No. CH-42959(2318)/2001 dated 24 April 2001. The Company started its commercial operation on 01st July, 2003. The Company went for Initial Public Offering (IPO) in 2018. The company is a publicly traded company and is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchanges Limited (CSE) since 10th October, 2018.

1.02 Address of the Registered Office and Factory

The registered and corporate office of the company is located at House # 65, Road No. 8/A (New), Dhanmondi, Dhaka-1209, Bangladesh.

Factory of the company is situated at 137, Joykrishnapur, Main Road, Maijdee Court, Noakhali.

1.03 Nature of Business:

The Company has engaged in manufacturing and marketing of pharmaceuticals finished products in the categories of Antibiotics, Analgesics, Anti diabetics, Narcotics, Anti pyretic, Anti inflammatory Drugs, Anti ulcerants, Antiemetic, Gastroprokinetic, Anti histamine, Anti spasmodic expectorants, Vitamins & Minerals medicines which is selling mainly in local market.

Also the company engaged in manufacturing and marketing of Animal Health care products in Bangladesh catering the needs of commercial animal producers.

2.00 Basis of Preparation of Financial Statements

2.01 Basis of Preparation and presentation of Interim Financial Statements

The Financial Statements have been prepared in accordance with International Accounting Standards (IAS) & International Financial Reporting Standards (IFRSs) as adopted in Bangladesh and in compliance with other relevant local laws including the Securities and Exchange Rules, 1987. The presentation of the interim financial statements and the accounting policies used in preparing them are consistent with those of the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

2.02 Statement of Compliance

The Financial Statements have been prepared on accrual basis in accordance with generally accepted accounting principle and practice in Bangladesh in compliance with the Companies Act, 1994, the Bangladesh Securities and Exchange Rules, 1987, The Financial Reporting Act, 2015, the Listing Regulation of Dhaka Stock Exchange Limited (DSE) and Chitagong Stock Exchange Limited (CSE) 2015 and International Financial Reporting Standards (IFRSs) as adopted by the Financial Reporting Council, Bangladesh and other relevant laws and regulations applicable in Bangladesh.

2.03 Application of Standards (IAS's)

As per para 12 of the Securities and Exchange Rules 1987, the company have been applied in the preparation of the financial statements for the period July-December, 2025 with the following International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) as adopted by The Financial Reporting Council (FRC) Bangladesh.

Name of the Accounting Standards	Reference No.
International Accounting Standards (IASs)	
Presentation of Financial Statements	IAS-1
Inventories	IAS-2
Statement of Cash Flows	IAS-7
Accounting Policies, Changes in Accounting Estimates and Errors	IAS-8
Events after the Reporting period	IAS-10
Income Taxes	IAS-12
Property, Plant & Equipment	IAS-16
Employee Benefits	IAS-19
The Effects of Changes in Foreign Exchange Rates	IAS-21
Borrowing Costs	IAS-23
Related Party Disclosures	IAS-24
Financial instruments: Presentation	IAS-32
Earnings Per Share	IAS-33
Interim Financial reporting	IAS-34
Impairment of assets	IAS-36
Provisions, Contingent Liabilities and Contingent Assets	IAS-37
Intangible Assets	IAS-38
International Financial Reporting Standards (IFRSs)	
Financial Instruments: Disclosure	IFRS-7
Operating Segments	IFRS-8
Financial Instruments	IFRS-9
Fair Value Measurement	IFRS-13
Revenue from Contracts with Customers	IFRS-15
Leases	IFRS-16

3.00 Property, Plant and Equipment

31 December, 2025

Particulars	Amount in Taka						
	Cost			Rate (%)	Depreciation		Written Down Value as at 31 December, 2025
	Balance as on 01 July, 2025	Addition during the period	Balance as on 31 December, 2025		Balance as on 01 July, 2025	Charge during the period	
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	342,774,940
Plant & Machinery	692,749,945	-	692,749,945	10%	478,552,539	10,711,148	203,486,258
Generator	12,396,170	-	12,396,170	10%	10,295,675	105,025	1,995,470
Building Decoration	121,235,416	-	121,235,416	10%	68,129,787	2,655,281	50,450,348
Electrical Installation	39,471,371	-	39,471,371	10%	20,116,570	967,740	18,387,061
Gas Installation	389,890	-	389,890	10%	328,474	3,071	58,345
Office Equipment	58,689,497	111,575	58,801,072	10%	33,830,917	1,245,680	23,724,475
Factory Equipment	64,813,573	-	64,813,573	10%	38,447,733	1,318,292	25,047,548
Furniture and Fixture	49,486,298	-	49,486,298	10%	32,108,029	868,913	16,509,356
Vehicle	129,904,291	-	129,904,291	20%	113,425,432	1,647,886	14,830,973
Power House	1,195,705	-	1,195,705	10%	1,016,775	8,947	169,983
Laboratory Equipment	99,725,018	-	99,725,018	10%	48,726,791	2,549,911	48,448,316
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	99,539,340	4,056,878	320,493,401
Total as on 31 December, 2025	2,036,921,733	111,575	2,037,033,308		944,518,062	26,138,772	1,066,376,474
30 June, 2025	2,036,849,283	72,450	2,036,921,733		886,684,640	57,833,422	1,092,403,671

Allocation of Depreciation

01/07/2025 to 31/12/2025

01/10/2025 to 31/12/2025

Charged during the period
Adjustment during the period

26,138,772

13,071,259

26,138,772

13,071,259

(a) Depreciation charged to cost of sales (Note-18.00)

24,309,058

12,156,271

(b) Depreciation charged to administrative expenses (Note-19.01)

1,568,326

784,276

(c) Depreciation charged to selling & distribution expenses (Note-19.02)

261,388

130,713

Total

26,138,772

13,071,260

31 December, 2024

Particulars	Amount in Taka						
	Cost			Rate (%)	Depreciation		Written Down Value as at 31 December, 2024
	Balance as on 01 July, 2024	Addition during the period	Balance as on 31 December, 2024		Balance as on 01 July, 2024	Charge during the period	
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	342,774,940
Plant & Machinery	692,749,945	-	692,749,945	10%	11,899,856	466,652,683	226,097,262
Generator	12,396,170	-	12,396,170	10%	116,694	10,178,981	2,217,189
Building Decoration	121,235,416	-	121,235,416	10%	2,950,313	65,179,475	56,055,941
Electrical Installation	39,471,371	-	39,471,371	10%	1,075,267	19,041,303	20,430,068
Gas Installation	389,890	-	389,890	10%	3,412	325,062	64,828
Office Equipment	58,689,497	-	58,689,497	10%	1,381,032	32,449,885	26,239,612
Factory Equipment	64,741,123	-	64,741,123	10%	1,460,744	36,986,989	27,754,134
Furniture and Fixture	49,486,298	-	49,486,298	10%	965,459	31,142,569	18,343,729
Vehicle	129,904,291	-	129,904,291	20%	2,059,857	111,365,574	18,538,717
Power House	1,195,705	-	1,195,705	10%	9,941	1,006,835	188,870
Laboratory Equipment	99,725,018	-	99,725,018	10%	2,833,235	45,893,556	53,831,462
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	4,160,901	95,378,439	328,711,180
Total	2,036,849,283	-	2,036,849,283		28,916,711	915,601,351	1,121,247,932

Allocation of Depreciation

Charged during the period
Adjustment during the period

01/07/2024 to
31/12/2024

28,916,711

28,916,711

26,892,541

1,735,003

289,167

28,916,711

01/10/2023 to
31/12/2023

14,458,356

14,458,356

13,446,271

867,501

144,584

14,458,356

(a) Depreciation charged to cost of sales (Note-18.00)

(b) Depreciation charged to administrative expenses (Note-19.01)

(c) Depreciation charged to selling & distribution expenses (Note-19.02)

Total

3.00 (A) Tax Base Value of Property, Plant and Equipment

31 December, 2025

Particulars	Amount in Taka									
	Cost			Rate (%)	Depreciation			Written Down Value as at 31 December, 2025		
	Balance as on 01 July, 2025	Addition during the period	Balance as on 31 December, 2025		Balance as on 01 July, 2025	Charge during the period	Balance as on 31 December, 2025			
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	342,774,940			
Plant & Machinery	692,749,945	-	692,749,945	20%	610,548,257	8,220,169	73,981,519			
Generator	12,396,170	-	12,396,170	20%	12,086,739	30,943	278,488			
Building Decoration	121,235,416	-	121,235,416	20%	100,474,460	2,076,096	18,684,860			
Electrical Installation	39,471,371	-	39,471,371	20%	31,995,795	747,558	6,728,018			
Gas Installation	389,890	-	389,890	20%	381,952	794	7,144			
Office Equipment	61,986,517	111,575	62,098,092	20%	49,932,375	1,216,572	10,949,145			
Factory Equipment	64,813,573	-	64,813,573	10%	39,936,891	1,243,834	23,632,848			
Furniture and Fixture	49,486,298	-	49,486,298	10%	32,949,968	826,817	15,709,513			
Vehicle	129,904,291	-	129,904,291	20%	115,421,213	1,448,308	13,034,770			
Power House	1,195,705	-	1,195,705	20%	1,170,636	2,507	22,562			
Laboratory Equipment	99,725,018	-	99,725,018	20%	74,546,085	2,517,893	22,661,040			
Factory Building & Warehouse	424,089,619	-	424,089,619	10%	282,299,858	7,089,488	134,700,273			
Total as on 31 December, 2025	2,040,218,753	111,575	2,040,330,328		1,351,744,229	25,420,979	663,165,120			
30 June, 2025	2,038,758,503	1,460,250	2,040,218,753		1,290,764,161	60,980,068	688,474,524			

31 December, 2024

Particulars	Amount in Taka						
	Cost			Rate (%)	Depreciation		Written Down Value as at 31 December, 2024
	Balance as on 01 July, 2024	Addition during the period	Balance as on 31 December, 2024		Balance as on 01 July, 2024	Charge during the period	
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	342,774,940
Plant & Machinery	692,749,945	-	692,749,945	20%	589,997,835	10,275,211	600,273,046
Generator	12,396,170	-	12,396,170	20%	12,009,381	38,679	12,048,060
Building Decoration	121,235,416	-	121,235,416	20%	95,284,221	2,595,120	23,356,075
Electrical Installation	39,471,371	-	39,471,371	20%	30,126,901	934,447	8,410,023
Gas Installation	389,890	-	389,890	20%	379,967	992	8,931
Office Equipment	60,598,717	-	60,598,717	20%	46,918,839	1,367,988	12,311,890
Factory Equipment	64,741,123	-	64,741,123	10%	37,172,815	1,378,415	26,189,893
Furniture and Fixture	49,486,298	-	49,486,298	10%	31,112,598	918,685	17,455,015
Vehicle	129,904,291	-	129,904,291	20%	111,800,443	1,810,385	16,293,463
Power House	1,195,705	-	1,195,705	20%	1,164,369	3,134	28,202
Laboratory Equipment	99,725,018	-	99,725,018	20%	68,251,352	3,147,367	28,326,299
Factory Building & Warehouse	424,089,619	-	424,089,619	10%	266,545,440	7,877,209	149,666,970
Total	2,038,758,503	-	2,038,758,503		1,290,764,161	30,347,632	717,646,710

4.00 Intangible Assets

31 December, 2025

Particulars	Cost			Rate (%)	Amortization			Written Down Value as at 31 December, 2025
	Balance as on 01 July, 2025	Addition during the period	Balance as on 31 December, 2025		Balance as on 01 July, 2025	Charge during the period	Balance as on 31 December, 2025	
	Software	3,297,020	-		3,297,020	875,485	121,077	
Total as on 31 December, 2025	3,297,020	-	3,297,020	875,485	121,077	996,562	2,300,458	
30 June, 2025	1,909,220	1,387,800	3,297,020	684,582	190,903	875,485	2,421,535	

Allocation of Amortization

Charged during the period
Adjustment during the period

Amortization charged to administrative expenses (Note-19.01)

Total

01/07/2025 to 31/12/2025

121,077

121,077

121,077

121,077

01/10/2025 to 31/12/2025

60,539

60,539

60,539

60,539

31 December, 2024

Particulars	Cost			Rate (%)	Amortization			Written Down Value as at 31 December, 2024
	Balance as on 01 July, 2024	Addition during the period	Balance as on 31 December, 2024		Balance as on 01 July, 2024	Charge during the period	Balance as on 31 December, 2024	
	Software	1,909,220	-		1,909,220	684,582	61,232	
Total	1,909,220	-	1,909,220	684,582	61,232	745,814	1,163,406	

5.00 Right of Use Assets (RoU)

Right-of-use assets (ROU) arise due to implementation of IFRS 16 from 1st July 2019. This is made up from use of building as lease of Corporate Office, Factory and Depot offices.

31 December, 2025

Particulars	Cost		Depreciation		Written Down Value as at 31 December, 2025
	Balance as on 01 July, 2025	Addition during the period	Balance as on 01 July, 2025	Charge during the period	
Right of Use Assets (RoU)	26,266,197	-	21,889,034	611,249	3,765,914
Total as on 31 December, 2025	26,266,197	-	21,889,034	611,249	3,765,782
30 June, 2025	26,266,197	-	20,614,235	1,274,799	4,377,163

Allocation of Depreciation	
Charged during the period	01/07/2025 to 31/12/2025
Adjustment during the period	01/10/2025 to 31/12/2025

Charged during the period
Adjustment during the period

611,249

309,048

611,249

309,048

611,249

309,048

611,249

309,048

Depreciation charged to administrative expenses (Note-19.01)

Total

31 December, 2024

Particulars	Cost		Depreciation		Written Down Value as at 31 December, 2024
	Balance as on 01 July, 2024	Addition during the period	Balance as on 01 July, 2024	Charge during the period	
Right of Use Assets (RoU)	26,266,197	-	20,614,235	656,349	4,995,613
Total	26,266,197	-	20,614,235	656,349	4,995,613

Amount in Taka	
31-Dec-25	30-Jun-25

6.00 Capital Work in Progress

A) Construction work-in-progress (Building)

Opening Balance	323,279,938	317,671,463
Addition during the year	1,176,815	5,608,475
Transfer to Property, Plant and equipment	-	-
Closing Balance	<u>324,456,753</u>	<u>323,279,938</u>

B) Plant and Machinery in transit and installation

Opening Balance	-	-
Addition during the year	-	-
Transfer to Property, Plant and equipment	-	-
Closing Balance	<u>-</u>	<u>-</u>
Total Closing Balance	<u>324,456,753</u>	<u>323,279,938</u>

A new building is being constructed in the factory premises located at Binodpur, Sadar, Noakhali to increase the overall production capacity of The Silva Pharmaceuticals Limited. The amount of machinery in transit represents the amount for opening the LC for the procurement of machineries for newly constructed factory building and increasing production capacity of existing factory which have not received yet.

7.00 Inventories

Raw Materials	252,645,446	256,370,266
Packing Materials	30,340,428	36,672,514
Spares & Tools	5,912,829	10,758,465
Promotional Materials & Gift items	14,479,572	16,895,726
Finished goods	100,475,400	105,874,652
Work in Process-Closing	2,590,244	16,439,992
Total	<u>406,443,919</u>	<u>443,011,615</u>

8.00 Trade and Other Receivable

Particulars

Trade Receivables	208,992,349	229,474,561
Accrued Interest	325,511	143,437
Closing Balance:	<u>209,317,860</u>	<u>229,617,998</u>

9.00 Advances, Deposits & Prepayments

Advances & Prepayments

Advance Income Tax	5,850,614	5,060,573
Advance against Purchase & Others	26,192,922	21,987,968
Advance against L/C	12,983,884	9,756,116
Advance against Travelling and Conveyance	4,694,758	2,640,738
Advance against Motor-cycle Expenses	4,015,726	4,210,305
Advance against Employee	2,812,755	1,853,740
Advance against Depot Rent	1,902,600	1,905,600
Prepayments of VAT	4,280,835	6,612,456
	<u>62,734,094</u>	<u>54,027,496</u>

Amount in Taka	
31-Dec-25	30-Jun-25

Deposits

Security Deposit

Bakhrabad Gas System Ltd
Bangladesh T & T Board
Power Development Board

48,610	48,610
40,600	40,600
288,000	288,000
377,210	377,210
63,111,304	54,404,706

Total:

Advances: These advances are un-secured but good and subsequently realized and/or adjusted.

Deposits: These balances represents security deposits made by the company for Gas connection, Telephone line connection & Electricity connection etc.

There is no claim against the company, which can be acknowledge as debt.

There is no aggregate amount due from the Directors (including Managing Director) and managing agents of the company and any of them severally or jointly with any other person.

10.00 Fixed Deposits Receipts (FDR)

Dutch Bangla Bank Ltd. Satmasjid Road branch
Shahjalal Islami Bank Ltd. Satmosjid Road Branch, Dhaka (Short Term Investment)

11,279,602	
62,931,089	64,030,846
74,210,691	64,030,846

Total

11.00 Cash and Cash Equivalents

Cash in Hand at factory
Cash in Hand at Head Office
Cash in Hand at Depot Office
Postal Imprest
Cash at Bank

8,788	5,670
7,014	10,057
29,934,847	20,011,676
3,065	3,065
7,430,394	18,742,881
37,384,108	38,773,349

Total:

12.00 Share Capital:

12.01 Authorized Share Capital :

15,00,00,000 ordinary shares of Tk 10/= each

1,500,000,000	1,500,000,000
----------------------	----------------------

12.02 Issued, subscribed and paid-up share capital

(a) By Cash

130,000,000 Ordinary shares of Tk. 10/- each fully paid in cash

1,300,000,000	1,300,000,000
---------------	---------------

(b) By Issue of Bonus Share

6,500,000 Ordinary shares of Tk. 10/- each fully paid-up as bonus shares

65,000,000	65,000,000
------------	------------

Total 13,65,00,000 ordinary shares of Taka 10/= each.

1,365,000,000	1,365,000,000
----------------------	----------------------

Composition of Shareholdings of Ordinary Shares:

Category of Shareholders	31-Dec-25		30-Jun-25	
	No. of Shares	%	No. of Shares	%
Directors/Sponsors	61,716,452	45.21%	61,716,452	45.21%
Financial and other Institutions	21,944,188	16.08%	22,990,859	16.84%
Foreign	11,025	0.01%	11,025	0.01%
General Public	52,828,335	38.70%	51,781,664	37.94%
Total	136,500,000	100.00%	136,500,000	100.00%

	Amount in Taka	
	31-Dec-25	30-Jun-25
13.00 Retained Earnings		
Opening balance	748,040,947	890,949,495
Dividend Paid	-	(9,957,150)
Net profit after tax during the period	(71,492,222)	(132,951,398)
Closing Balance:	676,548,725	748,040,947

14.00 Deferred Tax Liability

Deferred tax assets and liabilities have been recognised and measured in accordance with the provision of IAS 12 "Income Taxes". Related deferred tax expenses/income have been disclosed in note 27.02. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying Amount	Tax base value (*)	Taxable (deductible) Temporary	Applicable tax rate	Deferred tax Liability
31 December, 2025					
Property, Plant and Equipment	1,068,676,932	663,165,120	405,511,812	20.00%	81,102,362
Total deferred tax liabilities as on 31 December, 2025	1,068,676,932	663,165,120	405,511,812		81,102,362
30-Jun-25					
Property, Plant and Equipment	1,094,825,206	688,474,524	406,350,682	20.00%	81,270,136
Total deferred tax liabilities as on 30 June, 2024	1,094,825,206	688,474,524	406,350,682		81,270,136

(*) The schedule of Tax base value of Property Plant and equipment are shown in Note 03(A) in this financial statements.

15.00 Lease Liability

Opening Balance	3,377,163	4,617,962
Addition during the year	-	-
Finance Charge	185,610	454,922
Paid during the year	(796,860)	(1,695,721)
Closing Balance	2,765,913	3,377,163
Transferred to Current Maturity	(1,037,218)	(1,066,472)
Non-Current Portion	1,728,695	2,310,691

16.00 Trade and Other Payables

Trade Payable	14,190,692	9,971,279
Total	14,190,692	9,971,279

This represents the amount payable to suppliers of raw materials, packing materials, etc. All suppliers were paid on a regular basis.

17.00 Dividend Payable / Unclaimed Dividend

For the year 2023-2024	35,347	35,347
For the year 2022-2023	49,203	49,203
For the year 2021-2022	39,875	39,875
For the year 2020-2021	-	-
Interest (net off AIT & Bank charge)	12,144	14,733
Total	136,569	139,158

Amount in Taka	
31-Dec-25	30-Jun-25

18.00 Short Term Loan

SJIBL-BAI-MUAZZAL (FO)
 DBBL, Account No. 1714050001188
Total

13,592,209	12,912,624
15,668,875	15,307,113
29,261,084	28,219,737

19.00 Provision for expenses

Accrued Expenses
 Legal, Audit & Professional Fees
 Worker's Profit Participation Fund (WPPF)
 Provision for Income Tax
Total

	7,921,984	6,451,745
	1,670,000	3,380,750
Note- 19.02	8,770,020	6,469,906
	18,362,004	16,302,401

	01/07/2025 to 31/12/2025	01/07/2024 to 31/12/2024	01/10/2025 to 31/12/2025	01/10/2024 to 31/12/2024
20.00 Revenue				
Local Sales (Net)	174,973,907	201,634,883	88,559,817	102,530,143
Total:	174,973,907	201,634,883	88,559,817	102,530,143
21.00 Cost of goods sold				
Raw materials consumed	44,402,858	56,178,311	18,244,970	33,925,419
Packing materials consumed	18,607,295	24,506,468	7,469,393	11,761,456
Consumable item consumed	4,982,079	6,636,527	3,935,838	2,598,216
	67,992,232	87,321,306	29,650,201	48,285,091
Work in process- Opening	16,439,992	6,361,728	13,718,522	6,473,586
Work in process- Closing	(2,590,244)	(6,394,273)	(2,590,244)	(6,394,273)
Change in work in process	13,849,748	(32,545)	11,128,278	79,313
Total consumption	81,841,980	87,288,761	40,778,479	48,364,404
Manufacturing Overhead	15,021,525	17,804,122	7,332,385	8,245,953
Depreciation	24,309,058	26,892,541	12,156,271	13,446,271
Cost of production	121,172,563	131,985,424	60,267,135	70,056,628
Finished goods - Opening	105,874,652	109,462,185	99,967,458	98,106,750
Finished goods - Closing	(100,475,400)	(97,863,425)	(100,475,400)	(97,863,425)
Change of finished goods stock	5,399,252	11,598,760	(507,942)	243,325
Cost of Physician Sample	(3,427,733)	(2,038,247)	(1,736,484)	(867,322)
Cost of Goods Sold	123,144,082	141,545,937	58,022,709	69,432,631
21.01 Manufacturing overhead				
Salary, Wages & Allowances	9,237,929	9,998,588	4,458,746	4,877,879
Workers' benefit and welfare expense	362,029	589,611	185,851	339,485
Overtime	141,677	196,196	67,260	79,771
Staff Welfare Expenses	284,962	245,356	134,155	118,752
Laboratory Expenses	-	76,598	-	11,635
Postage & Stamp	19,547	12,139	11,283	5,579
Indirect materials	-	371,583	-	131,880
Electricity Bill	1,808,334	1,936,624	865,917	994,089
Gas & Water bill	103,665	117,606	54,595	63,499
Uniform and liveries	63,900	-	39,025	-
Carriage Inward	173,373	309,634	52,500	167,816
Medical Expenses	-	-	-	-
Power & Fuel	92,370	52,582	61,680	26,450
Printing & Stationery	100,474	197,848	5,344	13,543
Traveling & Conveyance	53,858	46,787	32,004	20,027
Factory Rent	840,000	720,000	420,000	360,000
Toll Charges	1,523,411	2,089,380	794,903	797,946
Repair & Maintenance	97,371	647,502	83,217	156,242
Sanitation & Cleaning	26,230	8,941	9,400	4,325
Entertainment	92,395	187,147	56,505	77,035
Total	15,021,525	17,804,122	7,332,385	8,245,953

Note- 21.01

	01/07/2025 to 31/12/2025	01/07/2024 to 31/12/2024	01/10/2025 to 31/12/2025	01/10/2024 to 31/12/2024
22.00 Administrative Expenses				
Salaries and allowances	12,036,530	13,408,722	5,939,818	6,452,670
Staff Welfare expenses	450,604	481,489	223,575	288,553
Printing & Stationery	24,719	73,845	6,840	31,175
Phone, Fax, Mobile and Internet Bill	274,828	432,246	139,546	287,040
Postage & Stamps	36,372	31,019	15,471	13,486
Traveling & Conveyance	816,988	575,121	407,329	291,316
Utility Bill	609,864	509,959	256,827	233,668
Entertainment	171,849	262,988	93,450	129,657
Donation and Subscription	97,231	125,400	87,231	20,000
Licenses Renewal and Registration Fe	202,640	78,200	24,664	-
Audit Fees	201,250	201,250	100,625	100,625
Directors Remuneration	-	500,000	-	200,000
Board meeting attending fees	150,000	187,500	150,000	187,500
Amortization of Intangible Assets	121,077	61,232	60,539	30,616
Depreciation of Right-of-use Assets	611,249	656,349	309,048	331,665
Depreciation	1,568,439	1,735,003	784,276	867,502
Repairs & Maintenance	395,605	571,730	151,390	353,270
RJSC Exp.	-	-	-	-
AGM & EGM Expenses	521,635	464,998	521,635	464,998
Meeting Expenses	54,642	-	54,642	-
Legal & Professional Fees	547,190	815,310	133,420	428,610
Total	18,892,712	21,172,361	9,460,326	10,712,351

23.00 Selling & Distribution Expenses

Salaries and allowances	57,299,710	68,063,224	29,646,711	34,502,260
Field forces expenses	20,024,284	12,495,434	11,307,032	6,574,166
Transportation & Handling Expenses	4,647,507	2,069,192	2,811,930	383,075
Staff Welfare expenses	745,985	1,165,629	366,370	532,200
Business Promotion Expenses	2,063,000	620,891	1,059,000	102,820
Repair & Maintenance	335,200	380,188	172,850	158,561
Traveling and conveyance Expenses	1,462,642	1,168,318	388,657	645,165
Water, electricity and Gas	459,352	295,354	306,245	146,481
Phone, Fax and Mobile Bill	216,910	124,902	102,860	87,252
Sample Expenses	3,427,733	2,038,247	1,736,484	867,322
Consumption of promotional material	4,408,669	1,966,098	2,327,232	730,476
Postage & Courier	535,051	562,993	250,005	255,990
Entertainment	141,520	154,016	68,801	67,343
Printing & Stationery	486,926	876,013	283,677	565,861
Depot Rent	2,176,760	2,177,100	1,132,590	1,092,825
Product Development Expenses	-	54,500	-	-
Training Expenses	168,360	718,177	163,660	341,881
Bank Charges	170,193	280,105	80,492	199,751
Depreciation	261,407	289,167	130,713	144,583
Vehicle Maintenance	914,306	1,201,562	583,754	323,968
Loading & Unloading	82,311	154,713	42,279	71,003
License fees & Renewals	167,600	136,981	19,750	26,743
Awards Expenses	1,685,070	-	1,685,070	-
Incentive Expenses	17,500	-	17,500	-
Total	101,897,996	96,992,804	54,683,662	47,819,726

01/07/2025 to 31/12/2025	01/07/2024 to 31/12/2024	01/10/2025 to 31/12/2025	01/10/2024 to 31/12/2024
-----------------------------	-----------------------------	-----------------------------	-----------------------------

24.00 Financial Expenses

Interest on Short Term Loan	2,381,646	1,681,648	1,763,226	1,080,692
Bank Charge & Commission	60,000	12,177	60,000	10,000
Interest expenses on lease liabilities	185,610	242,512	89,379	117,766
Total	2,627,256	1,936,337	1,912,605	1,208,458

25.00 Other Income

Interest on FDR	2,149,572	2,908,171	1,212,102	1,631,033
Interest on Bank STD Accounts	16,250	162,327	16,250	162,327
Sale of Wastage	62,435	294,995	-	132,645
Total	2,228,257	3,365,493	1,228,352	1,926,005

26.00 Workers Profit Participation and Welfare Fund (WPP&WF)

Net Profit before Contribution to WPP&WF	(69,359,882)	(56,647,063)	(34,291,133)	(24,717,018)
Rate of contribution to WPP&WF(%)	5.00%	5.00%	5.00%	5.00%
Workers Profit Participation and Welfare Fund (1	-	-	-	-

Note: Allocation for workers' profit participation fund has been made @ 5% of profit after charging such expenses as per provisions of the Bangladesh Labour Act, 2006 (Amendment 2013).

27.00 Income Tax expenses:

27.01 Current Tax Expenses

Net Profit before Income Tax	(69,359,882)	(56,647,063)	(34,291,133)	(24,717,018)
Accounting Depreciation	26,259,849	28,977,943	13,131,799	14,488,972
Tax Depreciation	(25,420,979)	(30,347,632)	(7,828,407)	(12,755,060)
Taxable Profit	(68,521,012)	(58,016,752)	(28,987,741)	(22,983,106)
Tax Rate	20.00%	20.00%	20.00%	20.00%
Current Tax Expenses during the period	(13,704,202)	(11,603,350)	(5,797,548)	(4,596,621)
Current Tax Expenses for the previous Assessment year	-	-	-	-
Total Current Tax Expenses	(13,704,202)	(11,603,350)	(5,797,548)	(4,596,621)

Minimum Tax Calculation

Calculation of Gross Receipts

Revenue from net sales	174,973,907	201,634,883	88,559,817	102,530,143
Other Income				
Interest on FDR	2,149,572	2,908,171	1,212,102	1,631,033
Interest on Bank deposit	16,250	162,327	16,250	162,327
Other Income	62,435	294,995	-	132,645
Total Gross Receipts	177,202,164	205,000,376	89,788,169	104,456,148
Minimum Tax (1.0% on total gross receipts except Interest income)	1,750,363	1,211,579	885,598	615,976
AIT paid on Interest income and Vehicle (As minimum Tax)	549,751	903,753	488,104	634,985
	2,300,114	2,115,332	1,373,702	1,250,961
Income Tax Provision whichever is higher	2,300,114	2,115,332	1,373,702	1,250,961

Income tax provision is higher between tax at regular rate on income and minimum tax on gross receipts U/S 163 (6) of Income Tax Act, 2023. Hence tax at regular rate is accounted for as it is higher than the minimum tax.

01/07/2025 to 31/12/2025	01/07/2024 to 31/12/2024	01/10/2025 to 31/12/2025	01/10/2024 to 31/12/2024
-----------------------------	-----------------------------	-----------------------------	-----------------------------

27.02 Deferred Tax Expenses/(Income)

Closing balance of deferred tax liability	81,102,362	80,952,926	81,102,362	80,952,925
Opening balance of deferred tax liability	81,270,136	80,678,988	81,186,652	80,815,956
Deferred Tax Expenses/(Income)	(167,774)	273,938	(84,290)	136,969

28.00 Earnings Per Share

Net profit after Tax (Numerator)	(71,492,222)	(59,036,333)	(35,580,545)	(26,104,948)
Weighted Average Number of Ordinary Shares (Den.)	136,500,000	136,500,000	136,500,000	136,500,000
Basic Earnings Per Share (EPS)	(0.52)	(0.43)	(0.26)	(0.19)

There is no potential dilutive claim during the period. Hence, no diluted EPS has been calculated during the reporting period.

29.00 Net Asset Value (NAV) Per Share

	Amount in Taka	
	31-Dec-25	30-Jun-25
Total Assets	2,187,367,349	2,252,320,821
Less: Total Liabilities	145,818,624	139,279,874
Net Asset Value	2,041,548,725	2,113,040,947
Total Number of Share outstanding	136,500,000	136,500,000
Net Asset Value (NAV) Per Share	14.96	15.48

Net asset value per share (NAV) has been computed by dividing total assets by the number of ordinary shares outstanding as on 31 December 2025 as per Notification of Bangladesh Securities & Exchange Commission (BSEC).

		Amount in Taka	
		01/07/2025 to 31/12/2025	01/07/2024 to 31/12/2024
30.00	Cash received from Customers		
	Sales during the year	174,973,907	201,634,883
	Opening Trade Receivable	229,474,561	255,718,828
	Closing Trade Receivable	(208,992,349)	(243,992,349)
	Total Cash Received from Customers	195,456,119	213,361,362
31.00	Cash received from non-operating income		
	Other income	2,228,257	3,365,493
	Opening interest receivable	143,437	411,593
	Closing interest receivable	(325,511)	(381,313)
	Total Cash received from non-operating income	2,046,183	3,395,773
32.00	Cash Paid to Suppliers		
	Purchase (Raw, Packing, Promotional, Indirect material and Spare parts)	55,082,205	68,699,024
	Opening Accounts Payable	9,971,279	7,162,713
	Closing Accounts Payable	(14,190,692)	(10,585,192)
	Closing Advance against Purchase & L/C	39,176,806	37,026,431
	Opening Advance against Purchase & L/C	(31,744,084)	(33,375,077)
	Total Cash Paid to Suppliers	58,295,514	68,927,899
33.00	Cash Paid to Employees		
	Salary, Wages & Allowances including contribution to PF	80,055,720	93,363,008
	Workers' benefit and welfare expense	362,029	589,611
	Overtime	141,677	196,196
	Directors Remuneration	-	500,000
	Board meeting attending fees	150,000	187,500
	Field forces expenses	20,024,284	12,495,434
	Worker's Profit Participation and Welfare Fund	-	-
	Opening Payable	5,986,548	8,429,371
	Closing Payable	(7,181,166)	(6,464,061)
	Closing Advance to Employee	2,812,755	2,512,755
	Opening Advance to Employee	(1,853,740)	(1,973,449)
	Total Cash Paid to Employees	100,498,107	109,836,365

		Amount in Taka	
		01/07/2025 to 31/12/2025	01/07/2024 to 31/12/2024
34.00	Cash Paid for Others		
	Manufacturing Overhead (excluding pay to employee & Supplier)	4,994,928	6,402,788
	Administrative Overhead (excluding Depreciation & pay to employee)	3,954,814	4,142,066
	Selling and Distribution overhead (excluding sample, promotional, Depreciation & pay to employee)	15,730,208	10,975,004
	Opening Liabilities for Expenses	3,845,947	4,058,407
	Closing Liabilities for Expenses	(2,410,818)	(4,218,012)
	Closing Advance deposit & prepayment	15,271,129	14,071,129
	Opening Advance deposit & prepayment	(15,746,309)	(15,583,921)
	Total Cash Paid for Others	25,639,898	19,847,461
35.00	Income Tax paid		
	Advance Income Tax paid	790,041	1,378,745
	Total Income Tax paid	790,041	1,378,745
36.00	Cash payment for Acquisition of Property, Plant and Equipment (PPE)		
	Property, Plant and Equipment addition during the year	111,575	-
	Addition from Capital Work-in-Progress	-	-
	Total Cash payment for Acquisition PPE	111,575	-
37.00	Net Operating Cash Flow Per Share(NOCFPS)		
	Net Operating Cash Flow	9,837,096	15,072,839
	Weighted Average Number of Ordinary Shares	136,500,000	136,500,000
	Net Operating Cash Flow Per Share(NOCFPS)	0.07	0.11

38.00 Disclosure as per requirement of the Companies Act, 1994

38.01 Disclosure as per Schedule XI, part I, para 4 of the Companies Act, 1994 are given below:

Sl. No.	Particulars	31-Dec-25	30-Jun-25
		Amount in Taka	
I	Receivables considered good and in respect of which the company is fully secured.	-	-
II	Receivables considered good for which the company holds no security other than the debtor's personal security.	208,992,349	229,474,561
III	Receivables considered doubtful or bad.	-	-
IV	Receivables due by directors or other officers of the company or any of them either severally or jointly with any other person or receivables due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
V	Receivables due by companies under the same management.	-	-
VI	The maximum amount due by directors or other officers of the company at any time during the year.	-	-
Total:		208,992,349	229,474,561

38.02 Disclosure as per Schedule XI, part I, para 6 of the Companies Act, 1994 are given below:

Sl. No.	Particulars	31-Dec-25	30-Jun-25
		Amount in Taka	
I	Advances, Deposits and Prepayments considered good and in respect of which the company is fully secured.	-	-
II	Advances, Deposits and Prepayments considered good for which the company holds no security.	51,588,065	45,699,923
III	Advances, Deposits and Prepayments considered doubtful or bad.	-	-
IV	Advances, Deposits and Prepayments due by directors or other officers of the company or any of them either severally or jointly with any other person or Advance, Deposits and Prepayment due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
V	Advance, Deposits and Prepayment due by companies under the same management.	-	-
VI	The maximum amount due by directors or other officers of the company at any time during the year.	11,523,239	8,704,783
Total:		63,111,304	54,404,706

38.03 Disclosure of Schedule XI, Part II, Para 3, of the Companies Act, 1994 are given below:

I. a. Turnover:

Particulars	01/07/2025 to 31/12/2025		01/07/2024 to 31/12/2024	
	Quantity (Pcs/PHs)	Amount in Taka	Quantity (Pcs/PHs)	Amount in Taka
Tablet	29,208,683	103,333,629	35,369,970	100,667,833
Capsule	5,228,916	46,304,117	6,558,935	45,690,135
Liquid	509,941	40,966,857	719,150	51,936,585
Dry Syrup	57,411	(15,630,696)	287,710	3,340,330
Total	35,004,951	174,973,907	42,935,765	201,634,883

b. No Commission paid to selling agents during the period.

c. No brokerage and discount paid on sales, other than the usual trade discount during the period.

d. (i) Raw Materials consumed:

Particulars	01/07/2025 to 31/12/2025		01/07/2024 to 31/12/2024	
	Quantity (KG)	Amount in Taka	Quantity (KG)	Amount in Taka
Opening stock	158,299	256,370,266	210,168	305,261,325
Purchase	38,339	40,678,038	42,430	45,060,441
Raw material available for consumption	196,638	297,048,304	252,598	350,321,766
Closing stock	(150,549)	(252,645,446)	(175,277)	(294,143,455)
Total Raw material consumed	46,089	44,402,858	77,321	56,178,311

(ii) Finished goods:

Particulars	01/07/2025 to 31/12/2025			01/07/2024 to 31/12/2024		
	Opening Qty.	Production Qty.	Closing Qty.	Opening Qty.	Production Qty.	Closing Qty.
Tablet (Pcs.)	16,521,477	30,000,000	17,312,794	16,521,477	33,295,000	14,446,507
Capsule (Pcs.)	6,418,438	6,048,000	7,237,522	6,418,438	8,198,000	3,057,503
Liquid (PHs.)	172,708	901,200	563,967	172,708	701,200	154,758
Dry Syrup (PHs.)	139,868	299,000	381,457	139,868	499,000	351,158
Total	23,252,491	37,248,200	25,495,740	23,252,491	42,693,200	23,009,926

ii. Disclosure as per requirement of Schedule XI, Part II, Note-5 of Para 3, of the Companies Act, 1994 are given below:

Employee Position of SILVA PHARMACEUTICALS LTD. as at 31 December, 2025

Salary Range (Monthly)	Total Employee	Officer & Staff		Worker & Employee	
		Head Office	Factory	Field	Factory
Number of Employees whose salary below taka 3,000 or 5,500 p.m.					
Number of Employees whose salary above taka 3,000 or 5,500 p.m.	624	51	22	455	96
For the period ended 31 December, 2025	624	51	22	455	96
For the year ended 30 June, 2025	615	51	22	446	96

38.04 Disclosure as per requirement of schedule XI, part II, Para 4 are given below:

July - December,
2025

(a) Managerial Remuneration paid or payable during the financial period to the directors, including managing-directors, a managing agent or manager;	
(b) Expenses re-imbursed to the Managing Agent;	Nil
(c) Commission or Other Remuneration payable separately to a managing agent or his associate;	Nil
(d) Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company.;	Nil
(e) The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial period.;	Nil
(f) Any other perquisite or benefits in cash or in kind stating approximate money value where practicable ;	150,000
(g) Other allowances and commission including guarantee commission.	Nil
(h) Pensions etc.	
(i) Pensions	Nil
(ii) Gratuities	Nil
(iii) Payments from a provident funds, in excess of own subscription and interest thereon	Nil
(iv) Compensation for loss of office	Nil
(v) Consideration in connection with retirement from office.	Nil

38.05 Disclosure as per requirement of schedule XI, Part II, Para 7 are given below:

For the half year period ended 31 December, 2025

Name of Item	Installed Capacity	Actual Production	% of Capacity Utilization
	Million Pcs/Ph.	Million Pcs/Ph.	
Tablet	100.00	30.00	30.00%
Capsule	29.00	6.05	20.86%
Liquid	1.00	0.90	90.12%
Dry Syrup	0.90	0.30	33.22%
Total	130.9	37.25	28.46%

38.06 Disclosure as per requirement of schedule XI, part II, Para 8 are given below:

- a) Value of imports calculated on C.I.F basis by the company during the financial period ended 31 December, 2025 in respect of Raw materials, Component and Spare parts and Capital Goods were as follows:

For the period ended 31 December, 2025

S.L	Particulars	Import		
		Unit	Quantity	Amount in BDT
i	Raw Materials	Kg/Ltr.	1,193	4,848,787
ii	Packing Materials	Pcs/Kg	7,267	3,750,795
iii	Components of Spare parts	Set	-	-
iv	Capital Goods	Set/Unit	-	-
Total			8,460	8,599,582

- b) The Company did not have any expenditure in foreign currency during the period on account of Royalty, Know-how, Professional consultation fees, Interest and other matters.

- c) Value of all imported raw materials, spare parts and components consumed during the financial period and the value of all indigenous

raw materials, spare parts and components similarly consumed and the percentage of each to the total consumption were as follows:

Particulars	Imported Value (in BDT)	Imported in percentage (%)	Indigenous Value (in BDT)	Indigenous in percentage(%)	Total
Raw Materials	4,764,874	10.73%	39,637,984	89.27%	44,402,858
Packing Materials	5,973,262	32.10%	12,634,033	67.90%	18,607,295
Components and Spare parts	-	0.00%	4,982,079	100.00%	4,982,079
Total	10,738,136	15.79%	57,254,096	84.21%	67,992,232

- d) No amount has been remitted during the year in foreign currencies on account of dividend with a specific mention of the number of non-residents shareholders, the number of shares held by them on which the dividends were due and the year to which the dividends, related.

- e) Earnings in foreign exchange classified under the following heads as follows:

- No export made during the period;
- No royalty, know-how, professional and consultation fees were received;
- No Interest and Dividend received;
- No Other income received

39.00 Reconciliation of Net income with Cash Flows from Operating Activities

Particulars	01/07/2025 to 31/12/2025	01/07/2024 to 31/12/2024
Net Profit before Income tax	(69,359,882)	(56,647,063)
<u>Adjustment for:</u>		
Depreciation	26,750,021	29,573,060
Amortization	121,077	61,232
Finance Expense for lease	185,610	242,512
	27,056,708	29,876,804
Decrease (Increase) in Advances, deposits & Prepayments.	(7,916,557)	(2,677,868)
Decrease (Increase) in Trade & Other Receivable	20,300,138	11,756,759
Increase (Decrease) in Accounts and Other Payable	4,219,413	3,422,479
Increase (Decrease) in Provision and Accruals	(240,511)	(1,805,705)
Decrease (Increase) in Inventories	36,567,696	32,526,178
Income Tax Paid	(790,041)	(1,378,745)
Net Cash Generated From Operating activities (indirect method)	9,836,964	15,072,839
Net Cash Generated From Operating activities (Direct method)	9,837,096	15,072,839

40.00 Disclosures as per IAS 24 Related Party disclosures are as follows:

The company carried out a number of transaction with related parties. The following are the related parties transactions of Silva pharmaceuticals Limited has been disclosed as required by IAS 24 Related Party Disclosures:

40.01 Disclosures as per paragraph 17 of IAS 24 are as follows:

(a) Short term employee benefits:

Name of the Related Parties	Nature of Relationship	Nature of Transaction	Value of goods / Services received during the period	Balance payable as on 31.12.2025
Mrs. Silvana Mirza	Chairman	Board Meeting Fees	18,750	-
Mrs. Samina Mirza	Director	Board & AC Meeting Fees	9,375	-
Mrs. Farhana Mirza	Director	Board & NRC Meeting Fees	-	-
Md. Monsur Rahman (Representative of Adarsha Fisheries & Poultry Farms Ltd.)	Director	Board, AC & NRC Meeting Fees	37,500	-
AKM Nuruzzaman	Director	Board Meeting Fees	9,375	-
ATM Sarwar Kamal Chowdhury	Independent Director	Board & AC Meeting Fees	37,500	-
Mr. Muhammad Moniruzzaman	Independent Director	Board Meeting Fees	37,500	-
Mr. A. R. Hassan Mirza	Executive Director & Sponsor Shareholder	Salary & Allowances	1,800,000	300,000
		Office Rent	796,860	132,810
Total			2,746,860	432,810

31-Dec-25

(b) Post-employee benefits

Nil

(c) Other long term benefits

Nil

(d) Termination benefits and

Nil

(e) Share-based payment

Nil

41.00 Significant Deviation

During the period, the net profit after tax decreased compared to the corresponding period of the previous year due to a decline in sales volume. EPS has decreased due to the decline in sales volume. NAVPS has decreased due to net loss incurred during this period. NOCFPS has decreased compared to the same period of the previous year due to a decrease in the collection from receivables as well as sales.